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microRNAs (miRNAs) are short non-coding RNAs that regulate gene expression by base 
pairing with their target messenger RNAs. Dysregulation of miRNAs is involved in the 
pathological initiation and progression of many human diseases. miR-221 and miR-222 
(miR-221/222) are two highly homologous miRNAs, and they are significantly overex-
pressed in several types of human diseases. Silencing miR-221/222 could represent a 
promising approach for therapeutic studies. In the present review, we will describe the 
potential value of miR-221/222 as diagnostic, prognostic, and therapeutic biomarkers in 
various diseases including cancer and inflammatory diseases.
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inTRODUCTiOn
microRNAs (miRNAs), a class of small (19–25 nt in length) single-stranded RNAs, are involved in 
posttranscriptional regulation of gene expression by base pairing with the complementary sequences 
in the 3′ untranslated region (3′UTR) of their target messenger RNAs (mRNAs) (1, 2). miRNAs are 
generated from the transcription of a long precursor (primary miRNA), which is then processed to 
a stem-loop precursor miRNA (pre-miRNA) by the nuclear protein Drosha in the nucleus (3). The 
DiGeorge syndrome Critical Region 8 protein (DGCR8) serves as a molecular ruler, directing the 
cleavage of Drosha (4). The pre-miRNA of 60–100 nt in length is cleaved by endoribonuclease Dicer 
to mature miRNA and antisense miRNA star products after the transportation of pre-miRNA to 
the cytoplasm by exportin-5 (5). The mature miRNA is incorporated into a RNA-induced silencing 
complex, which results in the inhibition of translation or degradation of the target mRNAs by bind-
ing to partially complementary sites (6). It has been widely shown that dysregulation of miRNAs 
is associated with the initiation, development, and progression of cancer or other diseases (7–9). 
miR-221 and miR-222, encoded in tandem from a gene cluster located on X chromosome (Xp11.3), 
contain identical seed sequences separated by 727 bases and are highly conserved in vertebrates (10). 
In healthy conditions, they have been found to regulate essential physiological vascular processes 
such as angiogenesis, neointimal hyperplasia, vessel wound healing, vascular aging, and atheroscle-
rotic vascular remodeling (11–14). These two highly homologous miRNAs are frequently acting as a 
gene cluster (miR-221/222) and have been extensively studied in many human malignancies. In this 
review, we focus on the current knowledge about the roles of miR-221/222 in the diagnosis, prog-
nosis, and therapy for breast cancer, liver cancer, pancreatic cancer, prostate cancer, gastric cancer, 
colorectal cancer (CRC), glioma, multiple myeloma (MM), and inflammatory diseases (Table 1).
TABLe 1 | Roles of miR-221/222 in human diseases.
Cancer Targets Biological function effects following microRnA antisense/inhibitor 
therapy
Correlation Reference
Breast cancer TRPS1, ADIPOR, SOCS1, 
CDKN1B, ERα, p27, TIMP3
Epithelial-to-mesenchymal 
transition (EMT), S-phase entry
Restore ERα expression and tamoxifen sensitivity; 
decrease cell growth; increase apoptosis
Prognosis (15–20)
Liver cancer Bone marrow failure, p27, 
p57, HDAC
Cell growth, apoptosis Increase apoptotic cell death; decrease tumor 
nodules
Detection and 
prognosis
(21–24)
Pancreatic 
cancer
TIMP-2, PTEN, p27, p57, 
and p53 upregulated 
modulator of apoptosis 
(PUMA), death receptor 
5, Bim
Cell proliferation, cell invasion, 
G1-phase arrest, apoptosis
Decrease cell proliferation Detection and 
prognosis
(25–29)
Antitumor effect
Prostate cancer p27, ARHI, SIRT1, HECTD, 
RAB1A
Cell cycle, apoptosis, androgen 
receptor signaling, EMT
Decrease tumor growth; increase apoptosis Tumor stage 
and prognosis
(10, 30–33)
Gastric cancer p27, p57, PTEN, RECK Cell cycle progression Decrease cell proliferation and migration; increase cell 
radiosensitivity
Detection and 
prognosis
(34–38)
Colorectal 
cancer
p57, RECK, PDLIM2, PTEN Cell cycle Decrease proliferation; increase apoptosis; increase 
radiosensitivity
Detection and 
prognosis
(39–43)
Glioma p27, p57, p53, PTPμ, 
TIMP3
Cell cycle, apoptosis, cell 
migration, radio-induced DNA 
damage repair
Decrease tumor growth; increase apoptosis, 
radiosensitivity
Detection and 
prognosis
(33, 44–49)
Multiple 
myeloma
p27, PUMA, PTEN, p57, 
Ki-67
Cell growth and apoptosis Antitumor activity, anti-proliferative effect, no organ-
related toxicity, restore melphalan sensitivity
Detection 
and genetic 
subtype
(50–53)
Malignant 
melanoma
p27Kip1/CDKN1B and the 
c-KIT receptor
Differentiation and enhanced 
proliferation of the melanoma 
cells
Proliferation, differentiation, apoptosis, and 
angiogenesis
Detection and 
prognosis
(54, 55)
PI3K/AKT
Rheumatoid 
arthritis
MMP-3, MMP-9, vascular 
endothelial growth factor
Cell growth Inhibit pro-inflammatory cytokines and cell invasion; 
increase cell apoptosis
Detection (56, 57)
Atherosclerosis PGC-1a, AdipoR1 Reactive oxygen species (ROS), 
cell apoptosis, NO synthesis
Ameliorate inflammation-induced cellular ROS 
production
Detection (58–61)
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BReAST CAnCeR
In basal-like breast cancer, stimulated transcription of miR-
221/222 by basal-like transcription factor FOSL1 (Fos-like 1, also 
named Fra1) can promote epithelial-to-mesenchymal transition 
(EMT) via targeting the 3′UTR of trichorhinophalangeal 1 
(TRPS1), leading to increased cell migration and invasion (15). 
Moreover, overexpressed miR-221/222 can promote the EMT 
in breast cancer by negatively regulating adiponectin receptor 1 
(ADIPOR1) (16). Li et al. also reported that a significantly higher 
expression of miR-221/222 was observed in highly invasive 
basal-like breast cancer, which could contribute to S-phase entry, 
cellular migration, and invasion through the downregulation of 
suppressor of cytokine signaling 1 (SOCS1) and cyclin-dependent 
kinase inhibitor 1B (CDKN1B) (17). Studies also showed that 
miR-221/222 enhanced breast cancer growth, migration, and 
invasion, meanwhile propagating the self-renewal of breast can-
cer stem cells by targeting phosphatase and tensin homolog/Akt 
(PTEN/Akt) pathway (62).
Overexpression of miR-221/222 can contribute to estrogen-
independent growth and fulvestrant resistance in breast cancer, 
which occurs together with β-catenin activation, dysregulation of 
transforming growth factor beta (TGF-β)-induced growth inhibi-
tion and p27 suppression (63). Increased tamoxifen resistance in 
breast cancer is associated with the inhibition of p27 regulated by 
elevating the expression of miR-221/222, and overexpression of 
p27 in the resistant cells can enhance their sensitivity to tamoxifen 
(64). Moreover, it has been reported that miR-221/222 negatively 
regulates estrogen receptor alpha (ERα), and knockdown of 
miR-221/222 can partially restore ERα expression and tamoxifen 
sensitivity (65). Downregulated expressions of p27 and ERα 
can enhance tamoxifen resistance by secreting miR-221/222 in 
exosomes for ER-positive and tamoxifen-sensitive breast cancer 
cells (66). Inhibition of miRNA-221/222 in ER-positive human 
breast adenocarcinoma cell line (MCF-7) can also increase 
the sensitivity to tamoxifen through the upregulation of tissue 
inhibitor of metalloproteinases-3 (TIMP3) (18). Therefore, miR-
221/222 might serve as potential therapeutic targets for drug 
resistance in breast cancer.
Nucleolin, an integral component of the microprocessor com-
plex consisting of Drosha and DGCR8, can regulate the expression 
of several miRNAs (such as miR-21, miR-221/222, and miR-103) 
that involved in breast cancer aggressiveness and drug resistance 
(63, 67–70). A specific aptamer AS1411 has been demonstrated 
to be able to modulate nucleolin binding to the microprocessor 
complex and affect the expressions of these above miRNAs by 
posttranscriptional regulation, thus reducing breast cancer 
metastasis both in  vitro and in  vivo (19). Moreover, nucleolin 
targeting treatment could also lead to decreasing cell growth and 
increasing apoptosis of fulvestrant-resistant breast cancer cells, 
thereby suggesting that targeting compounds of nucleolin has the 
potential to improve the sensitivity of drug resistant breast cancer 
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cells in the clinical practice (19). Falkenberg et al. have reported 
that high expression of miR-221/222 is significantly associated 
with the occurrence of distant metastases in breast cancer, thereby 
suggesting that miR-221/222 may become promising markers for 
breast cancer prognosis (20).
LiveR CAnCeR
Upregulated expression of miR-221/222 is involved in the 
progression of liver fibrosis by the activation of stellate cells 
(71). Moreover, miR-221/222 overexpression is linked to liver 
tumorigenesis from normal liver through cirrhosis to full-blown 
hepatocellular carcinoma (HCC), and miR-221/222 can enhance 
cell growth by targeting the cyclin-dependent kinase inhibitor 
p27 (72, 73).
Many studies have demonstrated that miR-221 can increase 
cell growth, inhibit apoptosis, and promote tumor progression 
in HCC (72, 74, 75). miR-221 overexpression is able to inhibit 
apoptosis of HCC-derived cell lines by targeting bone marrow 
failure (BMF) syndromes, and increased apoptotic cell death 
can be caused by miR-221 silencing (21). The hypothesis that 
increased expression of miR-221 might posttranscriptionally 
downregulate BMF to affect the TGF-β proapoptotic signals will 
require further investigations (76, 77). The increased expression 
of miR-221 contributes to the progression of liver cancer by 
downregulating the histone deacetylase (HDAC) through natural 
killer/cells-Jun (NK/c-Jun) activation and nuclear factor-kappa B 
p65 (NF-κBp65) nuclear translocation (22). Increase in miR-221 
expression and repression of its target genes (such as proapop-
totic BMF and cyclin-dependent kinase inhibitor p27/57) have 
been revealed in the liver of a miR-221 transgenic mouse model, 
and in vivo delivery of anti-miR-221 oligonucleotides can lead to 
significant reduction of the number and size of tumor nodules 
(23). The DNA hypomethylation at miR-221/222 locus and wild-
type tumor repressor protein 53 (TP53) activation by targeting 
MDM2 (E3 ubiquitin protein ligase homolog) is confirmed to 
be contributors to miR-221 overexpression in clinical specimens 
of HCC (78). It has been found that miR-221 is a core miRNA, 
which targets lots of HCC-related genes by feed-forward regula-
tory loops combining transcription factors from bioinformat-
ics analysis, and lentivirus-mediated miR-221 silencing can 
significantly suppress liver cancer cells as well as the growth of 
hepatoma xenografts in vivo (79).
Overexpressed miR-221 in serum samples of HCC patients 
correlates with tumor size, cirrhosis, tumor stage, and overall 
survival rate (24). An obvious relationship has been revealed 
between miR-221 levels in tissues and the migration, invasion, 
metastasis, tumor capsular infiltration, and time to recurrence 
after surgical resection of HCC (21, 74). Hence, miR-221 may be 
valuable for the prognosis of HCC patients and the use of miRNA 
silencing technology appears to be a promising therapeutic 
approach for HCC.
PAnCReATiC CAnCeR
Overexpressed miR-221/222 can contribute to the expres-
sion of matrix metalloproteinases-2 (MMP-2) and MMP-9 by 
directly targeting tissue inhibitor of MMP-2 (TIMP-2), thereby 
facilitating pancreatic cancer invasion (25). Transfection of 
pancreatic cancer cells with miR-221 inhibitor could inhibit 
cell proliferation by upregulation of phosphatase and tensin 
homolog (PTEN), p27, p57, and p53 upregulated modulator 
of apoptosis (PUMA) (26). Combination of chemotherapeutic 
drug sunitinib at low dosage and anti-miRNA oligonucleotides 
targeting the overexpressed miR-21, miR-221/222, and miR-10 
can achieve notable synergistic antitumor effect in pancreatic 
ductal adenocarcinoma cells, thereby indicating that this com-
binatory approach might be of great importance for therapeutic 
applications in this disease (27). Moreover, Tanaka et al. reported 
that metformin could suppress the expression of miR-221, 
which was responsible for G1-phase arrest and apoptosis via 
the upregulation of p27, death receptor 5, and Bim in pancreatic 
cancer cells (28).
In the specimens of pancreatic cancer tissue, miR-221 
and miR-222 were confirmed to be significantly upregulated, 
thereby suggesting that these two miRNAs had the potential to 
be used as diagnostic biomarkers for pancreatic cancer (80, 81). 
In addition, elevated expression of miR-222 has been reported 
to be an independent predictor of poor prognosis of pancreatic 
cancer (29).
PROSTATe CAnCeR
It was reported that overexpression of miR-221/222 might 
contribute to the progression of prostate carcinoma through 
downregulating cell cycle inhibitor p27 (10) and aplasia ras 
homolog member I (ARHI), which influenced cell cycle and 
apoptosis (82, 83). Yang et al. observed an increase in SIRT1, cell 
proliferation, and apoptosis and decrease in migration reduction 
after transfecting PC-3 cells with miR-221/222 inhibitor, thereby 
suggesting that the tumor-promoting role of miR-221/222 might 
be mediated by the activation of silent information regulator 
two homolog one (SIRT1) (30). The in vivo study by Mercatelli 
et al. also confirmed that miR-221/222 inhibition could lead to 
the upregulation of p27 and reduce the tumor growth of pre-
established prostate carcinoma xenografts, thereby indicating 
the therapeutic potential of miR-221/222 in prostate cancer (31). 
Wang et al. found that miR-221/222 promoted cell proliferation 
and repressed apoptosis of prostate cancer cells by repressing 
caspase-10, and prostate cancer cells were sensitized to tumor 
necrosis factor-a/cycloheximide (TNF-α/CHX)-induced apop-
tosis after miR-221/222 knockdown (84).
Androgen receptor (AR) signaling has a critical role in the 
development and progression of prostate cancer (85). Many 
studies have found that miR-221/222 is important in tumori-
genesis and progression from androgen-dependent to androgen-
independent (castration-resistant) prostate cancer (86, 87). 
Upregulation of miR-221/222 has been observed in the tumor 
tissues of patients with castration-resistant prostate cancer (88). 
Moreover, miR-221/222 was involved in the progression from 
hormone-sensitive to castration-resistant prostate cancer by 
downregulating HECTD2 and RAB1A, which subsequently led 
to reprograming of AR signaling, and activation of EMT and new 
cyclins (32).
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The levels of miR-221/222 were significantly higher in 
aggressive prostate cancer tissue samples than in non-aggressive 
prostate cancer tissue samples (83). It has been concluded that 
elevated miR-221/222 expression is significantly associated with 
a poor overall survival for patients with prostate cancer (33).
GASTRiC CAnCeR
The expression of miR-222/221 is significantly higher in gastric 
tumor samples compared to the corresponding normal tissues, 
and miR-222/221 can enhance gastric tumor growth in the mouse 
xenograft model (34). Meanwhile, miR-221/222 can facilitate 
the cell cycle progression of gastric cancer cells by downregu-
lating p27 and p57 (34). In addition, it has been indicated that 
increased miR-221/222 can significantly inhibit reversion-
inducing cysteine-rich protein with kazal motifs (RECK) whose 
aberrant methylation is useful for early diagnosis and treatment 
of peritoneal metastasis of gastric cancer, thereby resulting in 
enhanced proliferation and invasion of gastric cancer cells (35, 
89). Knockdown of miR-221/222 with anti-miRNA oligonucleo-
tides can inhibit cell growth, suppress cell invasion, and enhance 
cell radiosensitivity of human gastric cancer cells through the 
upregulation of PTEN (36). Xu et  al. reported that antisense 
oligonucleotide targeting miR-21, miR-106a, and miR-221 could 
effectively inhibit the proliferation and migration of human 
gastric cancer cells (90). Therefore, modulation of miR-221/222 
expression by antisense nucleic acid technology might be helpful 
for gene therapy of gastric cancer.
The increased expression of miR-221 in gastric cancer tissue 
samples is associated with advanced clinical stage, local invasion, 
lymphatic metastasis, and poor survival (91). The serum miR-221 
has been identified to be a potential biomarker for early detection 
of gastric cancer and significantly positive correlated with poor 
differentiation of gastric cancer according to a population-based 
study (37). Furthermore, miR-222 in plasma is significantly cor-
related with clinical stages, lymph nodes metastasis, and overall 
survival (38). These data indicate that circulating miR-221/222 
has potential diagnostic and prognostic values in gastric cancer.
COLOReCTAL CAnCeR
Sun et al. have demonstrated that miR-221 significantly overex-
pressed in 90% of CRC samples, and the miR-221 expression is 
positively correlated with an advanced tumor node metastasis 
stage and local invasion (39). They also confirmed that miR-
221-specific inhibitor could markedly inhibit CRC cell prolif-
eration and induce apoptosis by upregulating cyclin-dependent 
kinase inhibitor/p57 (CDKN1C/p57) (39). Moreover, miR-221 
overexpression enhanced CRC cell invasion and metastasis 
through targeting RECK (40). It has been reported that miR-
221/222 can reduce the ubiquitination and degradation of RelA 
and activator of transcription 3 (STAT3) proteins by directly 
binding to 3′UTR of PDLIM2, and miR-221/222 inhibitors 
can reduce CRC cell proliferation and colony formation (41). 
Formation of fewer tumors was observed after the injection of 
lentiviruses expressing miR-221/222 sponges (miR-221/222) in 
the mice model of colitis. As a competitive inhibitor of small 
RNAs in mammalian cells, miRNA sponges stably expressed 
miR-221/222 leading to reduced tumor volume and weight, as 
well as fewer Ki67-positive cells in tumors (41, 92). Moreover, 
inhibition of miR-221 could enhance the radiosensitivity of CRC 
cells by upregulating PTEN (42).
According to the study by Pu et  al., plasma miR-221 is a 
potential diagnostic biomarker for differentiating CRC patients 
from controls and elevated plasma miR-221 level is a significant 
prognostic factor for poor overall survival in CRC patients (43). 
A survival analysis has also indicated that high expression of miR-
221 in colon cancer is closely associated with a shorter survival 
time (93). The levels of miR-221 in stool samples from subjects 
with CRC were significantly higher, and the area under the curve 
value of stool miR-221 was 0.73, thereby suggesting that stool-
based miR-221 might be used as a potential detection biomarker 
for CRC (94).
GLiOMA
The enhanced expression of miR-221/222 in glioblastoma can 
promote S-phase entry by targeting the cell cycle inhibitors (p27 
and p57), and knockdown of miR-221/222 strongly reduced 
tumor growth in  vivo (44, 45). Upregulation of miR-221/222 
inhibits cell apoptosis by targeting PUMA in human glioma cells 
(46). Moreover, miR-222/221 overexpression can promote cell 
migration and growth by downregulating the protein tyrosine 
phosphatase μ (PTPμ) in glioblastoma (47, 95, 96). It was also 
found that miR-221/222 could regulate the invasion capability of 
glioma cells by directly targeting TIMP3 (33). Zhang et al. also 
reported that the plasma miR-221/222 family levels were found to 
be significantly upregulated in glioma patients, and high positive 
plasma miR-221 and miR-222 were both correlated with poor 
survival rate, which should be considered as a new additional tool 
to better characterize glioma (97).
Repression of miR-221 by a peptide nucleic acid could con-
tribute to growth inhibitory effects via significant increase in p27 
and TIMP3, thereby suggesting that sequence-selective targeting 
against miR-221 might have the potential for the treatment of 
human gliomas (98). Recently, administration of temozolomide 
in combination with radiotherapy was the best clinical approach 
for glioblastoma treatment (99, 100). Knockdown of miR-221/222 
sensitized glioma cells to temozolomide and increased apoptosis 
in human gliomas by regulating apoptosis independent of the p53 
status (48). The response to temozolomide is dependent on the 
intracellular level of the alkylating enzyme O6-methylguanine–
DNA methyltransferase (MGMT), and Quintavalle et  al. have 
showed that downregulation of MGMT targeted by miR-221/222 
may render cells unable to repair their genetic damage (101). It 
suggested that miR-221/222 could serve as potential therapeutic 
targets for radioresistance of glioblastoma cells since miR-
221/222 played a crucial role in radio-induced DNA damage 
repair and silencing of miR-221/222 could significantly increase 
radiosensitivity of glioblastoma cells by PTEN-independent inhi-
bition of Akt (49). Moreover, the combined anti-miR-221/222 
and radiotherapy is more efficient for the suppression of tumor 
growth than anti-miR-221/222 or radiotherapy alone in a murine 
glioblastoma model (49).
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The expression of miR-221/222 in high-grade gliomas is 
significantly increased compared with low-grade gliomas, and 
increased level of miR-221/222 is positively correlated with the 
degree of glioma infiltration that is associated with poorer overall 
survival (33). The study by Zhang et al. have demonstrated that 
plasma miR-221/222 levels are significantly upregulated in glioma 
patients and high plasma levels of miR-221/222 correlate with 
poor survival rate, thereby suggesting that miR-221/222 should 
be considered as prognostic biomarkers for glioma (97).
MULTiPLe MYeLOMA
The expression of miR-221/222 was revealed to be upregulated in 
human myeloma cell lines and primary MM tumors, and miR-
221/222 of plasma cells was at higher levels in t(4;14) patients 
than in the other classes (102, 103). Silencing miR-221/222 by 
specific inhibitors could result in a powerful antitumor activ-
ity in MM cells bearing t(4;14) and murine models of human 
MM via upregulation of p27, PUMA, PTEN, and p57 (50). At 
the same time, the antitumor activity of miR-221 inhibitors 
was higher than that of miR-222 inhibitors (50). The 13-mer 
locked nucleic acid-inhibitor-miR-221 (LNA-i-miR-221) had 
remarkable anti-proliferative effect on t(4;14)-translocated MM 
cells via strong derepression of p27, and significant antitumor 
activity against t(4;14) MM xenografts was also observed after 
2 weeks of exposure to LNA-i-miR-221 with upregulated p27 and 
reduced Ki-67 (51). Meanwhile, neither behavioral changes nor 
organ-related toxicity was observed in mice after the exposure 
to LNA-i-miR-221 according to the pathology examination (51).
Moreover, it is urgently needed to develop novel therapeutic 
strategies for MM since this disease can commonly progress 
to drug-refractory end stage that remains an obstacle to long-
term survival (104, 105). The expression level of miR-221/222 is 
negatively correlated with the melphalan sensitivity of MM cells, 
and miR-221/222 inhibition restores melphalan sensitivity and 
triggers apoptosis of MM cells with upregulation of proapoptotic 
Bcl-2-binding component 3 (BBC3)/PUMA, modulation of drug 
influx–efflux transporters SLC7A5/LAT1, and the ATP-binding 
cassette transporter multidrug resistance-associated protein 1 
(ABCC1/MRP1) (52). The combined treatment of severe com-
bined immunodeficient/non-obese diabetic mice bearing human 
melphalan-refractory MM xenografts with LNA-i-miR-221 
and melphalan can also overcome drug resistance and induce 
antitumor activity, which is associated with upregulation of 
BBC3/PUMA and downregulation of ABCC1 (52). Therefore, 
the miRNA-based therapies may be useful for clinical trials to 
overcome resistance in drug-refractory MM, especially miR-221. 
The miR-221 is confirmed to be significantly upregulated in 
the plasma samples of MM patients, and miR-221 is associated 
with chromosomal abnormalities, thereby suggesting that it has 
potential to be considered as clinical biomarkers for MM (53).
MALiGnAnT MeLAnOMA (MML)
Malignant melanoma is a fatal and aggressive neoplasm. miR-221 
is an abnormally expressed in MML cells, and it induces the malig-
nant phenotype through downmodulation of p27Kip1/CDKN1B 
and the c-KIT receptor; and the significantly increased level of 
miR-221 in patients’ circulating serum with MML is used as a 
new tumor marker, which is useful for the MML diagnosis, the 
in situ differentiating MML from stages I to IV MML, evaluating 
cancer progression, and monitoring patients during the follow-up 
period. In addition, the levels of miR-221 in serum are correlated 
with cancer thickness; miR-221 will be useful as a prognostic 
marker for MML patients (54). miR-222 in exosome can mediate 
transfer and sufficiently increase MML malignancy (55).
inFLAMMATORY DiSeASeS
The miR-221/222 is also involved in the pathogenesis of some 
inflammatory diseases, such as rheumatoid arthritis and athero-
sclerosis. The miR-221/222 has been found to be overexpressed in 
rheumatoid arthritis synovial fibroblasts, serum, and synovial tis-
sues of patients with rheumatoid arthritis (56, 57). Furthermore, 
downregulation of miR-221 in fibroblast-like synoviocytes could 
significantly inhibit the expression of pro-inflammatory cytokines 
and chemokine, inhibit cell migration and invasion, and induce 
cell apoptosis via inhibiting vascular endothelial growth factor 
(VEGF), matrix metalloproteinase-3 (MMP-3), and matrix met-
alloproteinase-9 (MMP-9) (56). The overexpression of miR-221 
can also decrease the level of BMP2, p-Smads, and osteogenic 
genes in degenerated annulus fibrosus cells (106). Overexpression 
of miR-221-inhibited adiponectin-stimulated nitric oxide (NO) 
in HUVECs indicated that miR-221 targeted AdipoR1 to regulate 
endothelial inflammatory response (58).
Serum miR-221/222 level significantly changed in patients 
with carotid atherosclerosis and coronary artery disease, thereby 
suggesting that they might be potential diagnostic biomarkers 
(59, 60). Xue et al. have found that overexpression of miR-19b 
and miR-221/222 in human aortic endothelial cells can induce 
reactive oxygen species (ROS) overproduction, which eventu-
ally leads to cell apoptosis and contributes to the pathogenesis 
of atherosclerosis (61). Moreover, inhibition of miR-19b and 
miR-221/222 expression with miRNA inhibitors can ameliorate 
the inflammation-induced cellular ROS production by regulat-
ing peroxisome proliferator-activated receptor-γ coactivator-1α 
(PGC-1α), thereby suggesting that these three miRNAs may 
be the potential therapeutic targets for atherosclerosis and 
coronary restenosis (61). The miR-221/-222 cluster orchestrates 
the antiviral and inflammatory immune response to viral infec-
tion of the heart, which demonstrated that the inhibition of 
miR-221/-222 increases viral load, inflammation, and overall 
cardiac injury upon viral myocarditis (107). It has been reported 
that miR-221 can suppress NO synthesis and activate nuclear 
factor-kappa B (NF-κB) signaling in human umbilical vein 
endothelial cells by targeting adiponectin receptor (AdipoR1), 
thereby suggesting that miR-221 might be involved in regulating 
endothelial inflammation response in vascular diseases (such as 
atherosclerosis) (58).
DiSCUSSiOn
The discovery of the important roles of miR-221/222 in cancer 
and inflammatory diseases has shown great potential in both 
FiGURe 1 | Schema summarizing the different cellular pathways targeted by miR-121/122.
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basic research and clinical applications. As one of the cancer 
biomarkers, miR-221/222 should be given more attention 
because of its wide existence and high correlation with cancer 
and inflammatory diseases. In this review, we have focused on 
the recent advances related to miR-221/222 for the diagnosis, 
prognosis, and therapy in breast cancer, liver cancer, pancreatic 
cancer, prostate cancer, gastric cancer, CRC, glioma, MM, MML, 
and inflammatory diseases.
miR-221/222 is overexpressed in breast cancer, liver cancer, 
pancreatic cancer, prostate cancer, gastric cancer, CRC, glioma, 
MM, and MML (54). Furthermore, miR-221/222 is almost 
undetectable in normal human melanocytes and is increasingly 
expressed in the cancers (54). miR-221/222 may mediate the 
functions of cancer cells to proliferate, differentiate, and invade 
(Figure 1). Therefore, high levels of miR-221/222 in serum may 
be useful as a prognostic marker and develop some new diagnosis 
and prognosis methods for the cancers; and inhibition or silence 
miR-221/222 may develop some treatment methods for the 
cancers.
Inflammation is causally linked to numerous clinical patholo-
gies, including cancer, heart disease, and type 2 diabetes. Pro-
inflammatory macrophages have been widely implicated in the 
initiation and progression of these diseases and therefore are a 
key target for therapeutic intervention. miR-221/222 families 
play crucial roles in these diseases through different signaling 
pathways by regulating the expression of different proteins. 
For example, miR-221/222 regulates endothelial nitric oxide 
synthase protein levels after Dicer silencing targeting c-Kit for 
the inhibition of angiogenesis. Autophagic signaling networks are 
modulated by miR-221/222 in cancer. In inflammatory diseases, 
miR-221/222 expression leads to the inhibition of VEGF, MMP-
3, and MMP-9; ROS overproduction by regulating PGC-1α; 
suppression of NO synthesis; and activation of NF-κB signaling 
by targeting AdipoR, thereby regulating the endothelial inflam-
matory response. Since miR-221/222 families have extensively 
been studied in cancer network and inflammatory diseases, we 
consider that miR-221/222 acts as promising biomarkers for 
cancer and inflammatory diseases and it would offer a new way 
in molecular targeting cancer treatment. Like other miRNAs, 
the miR-221/222 cluster plays a remarkable role in cancer and 
inflammatory diseases. Due to the complexity in diagnosis and 
treatment of these diseases, miR-221/222 has great potential 
value as a new biomarker. A combined use of miR-221/222 and 
other tumor biomarkers will maximum benefit the diagnosis, 
prognosis, and treatment.
The serum level of miR-221/222 will be useful as a prognostic 
marker and develop some new diagnosis and prognosis methods 
for some cancers and inflammatory diseases; if the serum level of 
miR-221/222 significantly increases than in healthy controls, they 
should be considered cancer candidates; and inhibition, control, 
or silence miR-221/222 will develop some treatment methods for 
the cancers.
COnCLUSiOn
In this review, we focused on each disease for a comprehensive 
analysis, which is different from previous reviews. Current results 
in the literature suggest that miR-221/222 has the potential to 
be considered as novel diagnostic and prognostic biomarkers for 
these diseases. Moreover, particular attention should be given to 
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the gene therapies based on miR-221/222 for the development of 
novel therapeutics for cancer and inflammatory diseases.
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